Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
February 14, 2024 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth...
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
February 13, 2024 16:05 ET
|
Codexis, Inc.
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and...
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
February 01, 2024 16:05 ET
|
Codexis, Inc.
BEVERLY, Mass. and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ: CDXS), a leading enzyme...
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
December 27, 2023 08:30 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé...
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
December 13, 2023 16:06 ET
|
Codexis, Inc.; Aldevron
REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with...
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
December 13, 2023 16:05 ET
|
Codexis, Inc.
Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. ...
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing
December 11, 2023 07:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8,...
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
November 28, 2023 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event...
Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference
November 14, 2023 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler...
Codexis Reports Third Quarter 2023 Financial Results
November 02, 2023 16:05 ET
|
Codexis, Inc.
Company Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis™ Platform for RNAi Therapeutics Production by End of Year Strong Financial Position Enables Projected Runway to...